Oppenheimer & Co. Inc. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Oppenheimer & Co. Inc. boosted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 34.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,947 shares of the company’s stock after purchasing an additional 21,128 shares during the quarter. Oppenheimer & Co. Inc. owned about 0.11% of Trevi Therapeutics worth $274,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in TRVI. Logos Global Management LP boosted its position in shares of Trevi Therapeutics by 27.3% in the 2nd quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock valued at $8,344,000 after purchasing an additional 600,000 shares during the period. Opaleye Management Inc. lifted its stake in Trevi Therapeutics by 4.3% in the first quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock valued at $9,125,000 after buying an additional 110,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Trevi Therapeutics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after acquiring an additional 60,249 shares during the period. Ally Bridge Group NY LLC purchased a new position in shares of Trevi Therapeutics during the second quarter worth approximately $4,395,000. Finally, Rosalind Advisors Inc. increased its holdings in shares of Trevi Therapeutics by 50.3% in the 2nd quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after acquiring an additional 465,561 shares during the period. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TRVI has been the subject of a number of recent research reports. Raymond James initiated coverage on Trevi Therapeutics in a research report on Friday, August 30th. They set an “outperform” rating and a $9.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Tuesday, October 22nd. Leerink Partners began coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Finally, Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Trevi Therapeutics has a consensus rating of “Buy” and an average target price of $7.43.

Insider Buying and Selling

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total transaction of $33,162.62. Following the completion of the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. This represents a 4.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 21,595 shares of company stock worth $64,886. Corporate insiders own 24.37% of the company’s stock.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $2.91 on Friday. The firm has a market capitalization of $223.69 million, a PE ratio of -6.61 and a beta of 1.01. Trevi Therapeutics, Inc. has a 1-year low of $0.97 and a 1-year high of $4.00. The business’s fifty day moving average price is $3.11 and its two-hundred day moving average price is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the prior year, the business posted ($0.08) earnings per share. Equities research analysts expect that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.